Biren Amin
Stock Analyst at Piper Sandler
(2.23)
# 2,798
Out of 4,996 analysts
60
Total ratings
47.17%
Success rate
-3.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $76.63 | +23.97% | 2 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $11 → $15 | $18.36 | -18.30% | 11 | Jul 29, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $63 → $68 | $50.05 | +35.86% | 3 | Jul 14, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $1.99 | +201.51% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $0.91 | +339.56% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $6.15 | +176.42% | 2 | May 16, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $7 | $1.25 | +460.00% | 3 | May 14, 2025 | |
| LENZ LENZ Therapeutics | Maintains: Overweight | $38 → $51 | $42.03 | +21.34% | 1 | Apr 14, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $38 | $23.26 | +63.37% | 1 | Mar 31, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | $12 | $3.74 | +220.86% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $25.57 | +177.67% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $12.11 | +189.02% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $11.59 | +81.19% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $79.69 | +44.31% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $22.39 | +42.92% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.95 | -24.05% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $12.53 | +19.71% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.55 | +4,416.13% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.67 | +7,522.18% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.07 | +373.37% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $3.25 | +946.15% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $19.05 | +2,524.67% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $7.70 | +81.82% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $563.90 | +22.54% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $2.90 | +244.83% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $23.58 | +328.33% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $142.00 | -51.41% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $385.74 | -59.82% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $2.10 | +6,376.19% | 4 | Mar 6, 2017 |
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $76.63
Upside: +23.97%
Sarepta Therapeutics
Jul 29, 2025
Maintains: Neutral
Price Target: $11 → $15
Current: $18.36
Upside: -18.30%
BridgeBio Pharma
Jul 14, 2025
Maintains: Overweight
Price Target: $63 → $68
Current: $50.05
Upside: +35.86%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $1.99
Upside: +201.51%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $0.91
Upside: +339.56%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $6.15
Upside: +176.42%
Allogene Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.25
Upside: +460.00%
LENZ Therapeutics
Apr 14, 2025
Maintains: Overweight
Price Target: $38 → $51
Current: $42.03
Upside: +21.34%
Centessa Pharmaceuticals
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $23.26
Upside: +63.37%
Compass Therapeutics
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $3.74
Upside: +220.86%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $25.57
Upside: +177.67%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $12.11
Upside: +189.02%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $11.59
Upside: +81.19%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $79.69
Upside: +44.31%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $22.39
Upside: +42.92%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.95
Upside: -24.05%
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $12.53
Upside: +19.71%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.55
Upside: +4,416.13%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.67
Upside: +7,522.18%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.07
Upside: +373.37%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $3.25
Upside: +946.15%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $19.05
Upside: +2,524.67%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $7.70
Upside: +81.82%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $563.90
Upside: +22.54%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $2.90
Upside: +244.83%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $23.58
Upside: +328.33%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $142.00
Upside: -51.41%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $385.74
Upside: -59.82%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $2.10
Upside: +6,376.19%